FH
FHTX.US Foghorn Therapeutics Inc
- Market cap
- USD 124M
- P/E
- 23.0x
- P/B
- 2,005.35x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is FHTX.US undervalued?
Graham numberThe Graham number of Foghorn Therapeutics Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Foghorn Therapeutics Inc fundamental analysis
No fundamental analysis for Foghorn Therapeutics Inc yet.
Foghorn Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Foghorn Therapeutics Inc
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; a…
Full company profileFoghorn Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Foghorn Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 430K | 1.32M | 19.2M | 34.2M | 22.6M | 30.9M | 137M |
| Gross Profit | -379K | -1.79M | -57.3M | 1.32M | 19.2M | 34.2M | 22.6M | 27.6M | 137M |
| Operating Income | -26.0M | -51.1M | -68.5M | -101M | -117M | -108M | -103M | -82.1M | 35.0M |
| EBITDA | -25.6M | -49.9M | -67.2M | -96.2M | -114M | -90.7M | -97.2M | -71.0M | 42.4M |
| Net Income | -26.3M | -51.1M | -68.8M | -101M | -109M | -98.4M | -86.6M | -74.3M | 41.4M |
| EPS | -1.34 | -1.39 | -1.87 | -2.73 | -2.62 | -2.34 | -1.58 | -1.18 | 0.57 |
| Balance Sheet | |||||||||
| Total Assets | 43.1M | 22.3M | 256M | 520M | 405M | 286M | 284M | 198M | 191M |
| Total Liabilities | 82.3M | 110M | 109M | 423M | 405M | 363M | 330M | 307M | 205M |
| Shareholders' Equity | -39.3M | -88.0M | 146M | 96.9M | 112K | -77.2M | -45.5M | -109M | -14.1M |
| Cash & Short-term Investments | 40.0M | 15.0M | 186M | 154M | 346M | 234M | 244M | 159M | 156M |
| Total Debt | 7.03M | 16.6M | 82.0M | 58.3M | 51.5M | 45.1M | 37.1M | 41.3M | 43.9M |
| Cash Flow | |||||||||
| Operating Cash Flow | -22.6M | -46.3M | -31.3M | -50.3M | 194M | -118M | -100M | -86.1M | -81.8M |
| Capital Expenditure | 1.54M | 968K | 16.2M | 3.31M | 1.21M | 1.22M | 906K | 50.0K | 76.0K |
| Free Cash Flow | -24.2M | -47.3M | -47.5M | -53.6M | 192M | -119M | -101M | -86.1M | -81.9M |
| Ratios | |||||||||
| ROE | - | - | -47.1% | -104.6% | -97,208.7% | - | - | - | - |
| ROA | -61.2% | -228.8% | -26.9% | -19.5% | -26.9% | -34.4% | -30.5% | -37.5% | 21.7% |
| Net Profit Margin | - | - | -16,000.0% | -7,681.6% | -566.2% | -288.2% | -383.2% | -240.3% | 30.2% |
| Debt to Equity | - | - | 0.56x | 0.60x | 459.88x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Foghorn Therapeutics Inc dividends
Foghorn Therapeutics Inc has not paid dividends in the last 8 fiscal years.
Who owns Foghorn Therapeutics Inc
- Insiders 14.00%
- Institutions 82.09%
- Public & others 3.91%
- Shares outstanding 60.0M
- Free float 26.2M
Top funds holding FHTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 1.83M | 3.09% | 0.00% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.12M | 1.88% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 877K | 1.48% | 0.00% | Oct 2026 |
| Fidelity Growth Company K6 | 503K | 0.85% | 0.00% | Aug 2026 |
| Fidelity Small Cap Index | 400K | 0.67% | +1.00% | Aug 2026 |
| Fidelity Select Biotechnology | 352K | 0.59% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 346K | 0.58% | -0.38% | Oct 2026 |
| Belfius Equities Cure C Cap | 314K | 0.53% | 0.00% | Apr 2026 |
| Fidelity Series Growth Company | 270K | 0.45% | -3.33% | Aug 2026 |
| JPMorgan US Small Company L | 260K | 0.44% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 245K | 0.41% | -0.19% | Oct 2026 |
| Vanguard Russell 2000 ETF | 211K | 0.36% | +0.83% | Sep 2026 |
| Fidelity Extended Market Index | 182K | 0.31% | +37.46% | Sep 2026 |
| iShares Micro-Cap ETF | 109K | 0.18% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 96.8K | 0.16% | +10.06% | Sep 2026 |
| Vanguard VIF Small Co Gr | 85.0K | 0.14% | +58.39% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 70.5K | 0.12% | 0.00% | Oct 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 63.9K | 0.11% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 62.1K | 0.10% | -0.05% | Sep 2026 |
| LVIP JPMorgan Small Cap Core Standard | 56.5K | 0.10% | 0.00% | Sep 2026 |
Top institutions holding FHTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Flagship Ventures Management, Inc. | 12.7M | 21.34% | 0.00% | Jun 2026 |
| Bvf Inc | 5.84M | 9.84% | 0.00% | Jun 2026 |
| FMR Inc | 5.71M | 9.61% | -5.64% | Jun 2026 |
| Deerfield Management Co | 4.39M | 7.40% | 0.00% | Jun 2026 |
| BlackRock Inc | 2.63M | 4.42% | +11.08% | Jun 2026 |
| Euclidean Capital LLC | 1.57M | 2.65% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.49M | 2.52% | -0.03% | Jun 2026 |
| Geode Capital Management, LLC | 911K | 1.53% | +7.39% | Jun 2026 |
| Siren, L.L.C. | 721K | 1.21% | 0.00% | Jun 2026 |
| State Street Corp | 697K | 1.17% | +2.60% | Jun 2026 |
| Ameriprise Financial Inc | 559K | 0.94% | +24.44% | Jun 2026 |
| Renaissance Technologies Corp | 378K | 0.64% | -7.01% | Jun 2026 |
| Candriam Luxembourg S.C.A. | 314K | 0.53% | 0.00% | Jun 2026 |
| Northern Trust Corp | 310K | 0.52% | +12.29% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 305K | 0.51% | +0.55% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 304K | 0.51% | +18.95% | Jun 2026 |
| Birchview Capital, LP | 282K | 0.47% | +0.07% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 264K | 0.45% | +9.91% | Jun 2026 |
| Qube Research & Technologies | 203K | 0.34% | +150.12% | Jun 2026 |
| Woodline Partners LP | 202K | 0.34% | +12.10% | Jun 2026 |
Foghorn Therapeutics Inc company profile
- Company name
- Foghorn Therapeutics Inc
- Ticker
- FHTX.US
- Exchange
- USA Stocks
- Listed since
- Oct 23, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 106
- Fiscal year end
- December
- Address
- 99 Coolidge Avenue, Watertown, MA, United States, 02472
- Phone
- 617 586 3100
- Website
- foghorntx.com
About Foghorn Therapeutics Inc
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Foghorn Therapeutics Inc management
10- Dr. Douglas G. Cole M.D.Founder & Independent Chairman of the Board · born 1960
- Mr. Adrian H. B. GottschalkPresident, CEO & Director · born 1976
- Dr. Steven F. Bellon Ph.D.Chief Scientific Officer · born 1965
- Dr. Alfonso Quintas Cardama M.D.Chief Medical Officer · born 1971
- Dr. Gerald R. Crabtree M.d.Founder & Member of Scientific Advisory Board
- Mr. Ryan D. MaynardChief Financial Officer · born 1969
- Ms. Karin HellsvikChief of Staff to the CEO, VP, Head of Corporate Affairs, Investor Relations & Operations
- Mr. Michael J. LaCascia J.D.Chief Legal Officer · born 1965
- Mr. Saurabh Sewak Ph.D.Vice President of Corporate Development
- Mr. Carlos CostaChief People Officer · born 1973